ArticleDrug and alcohol dependence reports2026
Cognitive performance and subjective effects the morning after last use of smoked cannabis by adults who use cannabis frequently: An observational study.
Article in Drug and alcohol dependence reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To examine next-day cognitive performance and subjective drug effects after smoking cannabis and to assess associations between performance and cannabinoid concentrations in blood and oral fluid. Methods: In this observational study, healthy adults who regularly used cannabis (mean age 30 years; n = 65) smoked a legally purchased pre-rolled "joint" at night and were tested the next day, 12-15 h later. Healthy adults with no past-month cannabis use served as a matched control group (mean age 30; n = 65). Participants completed cognitive tasks (verbal free recall [VFR], Trail Making Test [TMT]), subjective effects questionnaires (including visual analogue scales [VAS]), and provided blood and oral fluid samples for quantification of delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and metabolites. Linear regression models compared groups across cognitive/subjective outcomes, while Pearson correlations assessed associations between cannabinoid concentrations and performance. Results: There were no significant group differences on any cognitive measure. The cannabis group had significantly elevated VAS ratings (e.g., feeling a drug effect, Δmean=12.54, Conclusions: There was no measurable next-day cognitive differences between groups, despite some subjective intoxication in the cannabis group. Nonetheless, higher THC potency and elevated cannabinoid concentrations were associated with poorer verbal memory and processing speed, suggesting potential next-day impairment with high-THC products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.